Phase II Study of Cixutumumab in Combination With Temsirolimus in Pediatric Patients and Young Adults With Recurrent or Refractory Sarcoma: A Report From the Children's Oncology Group

Wagner Lars M.; Fouladi Maryam; Ahmed Atif; Krailo Mark D.; Weigel Brenda; DuBois Steven G.; Doyle L. Austin; Chen Helen; Blaney Susan M.

首页> 外文期刊>Pediatric blood & cancer >Phase II Study of Cixutumumab in Combination With Temsirolimus in Pediatric Patients and Young Adults With Recurrent or Refractory Sarcoma: A Report From the Children's Oncology Group

【24h】

Phase II Study of Cixutumumab in Combination With Temsirolimus in Pediatric Patients and Young Adults With Recurrent or Refractory Sarcoma: A Report From the Children's Oncology Group

机译：西昔单抗与替莫罗莫司联合用于儿童患者和青壮年复发或难治性肉瘤的第二阶段研究：儿童肿瘤学组的报告

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe combined inhibition of insulin-growth factor type 1 receptor (IGF-1R) and the mammalian target of rapamycin (mTOR) has shown activity in preclinical models of pediatric sarcoma and in adult sarcoma patients. We evaluated the activity of the anti-IGF-1R antibody cixutumumab with the mTOR inhibitor temsirolimus in patients with relapsed or refractory Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and other soft tissue sarcoma, using the recommended dosages from a pediatric phase I trial.

机译：背景胰岛素生长因子1型受体（IGF-1R）和哺乳动物雷帕霉素靶点（mTOR）的联合抑制作用在小儿肉瘤的临床前模型和成年肉瘤患者中均显示出活性。我们使用儿童I期试验的推荐剂量，评估了mTOR抑制剂西罗莫司与抗IGF-1R抗体西妥木单抗在复发或难治的尤因肉瘤，骨肉瘤，横纹肌肉瘤和其他软组织肉瘤中的活性。

著录项

来源
《Pediatric blood & cancer》 |2015年第3期|共5页
作者
Wagner Lars M.; Fouladi Maryam; Ahmed Atif; Krailo Mark D.; Weigel Brenda; DuBois Steven G.; Doyle L. Austin; Chen Helen; Blaney Susan M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类儿科学;
关键词
cixutumumab; pediatric sarcoma; Phase II; temsirolimus;

机译：西昔单抗;小儿肉瘤;第二阶段;西罗莫司;

相似文献

外文文献
中文文献
专利

1. Phase II Study of Cixutumumab in Combination With Temsirolimus in Pediatric Patients and Young Adults With Recurrent or Refractory Sarcoma: A Report From the Children's Oncology Group [J] . Wagner Lars M., Fouladi Maryam, Ahmed Atif, Pediatric blood & cancer . 2015,第3期

机译：西昔单抗与替莫罗莫司联合用于儿童患者和青壮年复发或难治性肉瘤的第二阶段研究：儿童肿瘤学组的报告
2. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: AChildren's Oncology Group Phase I Consortium Report [J] . Fouladi Maryam, Perentesis John P., Wagner Lars M., Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第7期

机译：我将Cixutumumab（IMC-A12）与Temsirolimus（CCI-779）组合的I阶段研究，在患有经常性实体瘤的儿童中：ACHILDREN的肿瘤学组I联盟报告
3. Phase 1 Trial of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors: A Children's Oncology Group Study [J] . Bagatell Rochelle, Norris Robin, Ingle Ashish M., Pediatric blood & cancer . 2014,第5期

机译：替莫罗莫司与伊立替康和替莫唑胺联用在儿童，青少年和年轻成人复发或难治性实体瘤中的一期试验：儿童肿瘤学组研究
4. Evaluating the Use of Patient-Reported Non-Routine Events in Pediatric and Radiation Oncology: A Pilot Study [C] . Kathryn G. Tippey, Jason M. Slagle, Ryan K. Cleary, Proceedings of the Human Factors and Ergonomics Society 2018 annual meeting . 2018

机译：评价在小儿和放射肿瘤学中患者报告的非常规事件的使用：一项初步研究
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Phase II Study of Cixutumumab in Combination with Temsirolimus in Pediatric Patients and Young Adults with Recurrent or Refractory Sarcoma: A Report from the Children’s Oncology Group [O] . Lars M. Wagner, Maryam Fouladi, Atif Ahmed, -1

机译：西昔单抗与替莫罗莫司联合用于儿童患者和青壮年复发或难治性肉瘤的第二阶段研究：儿童肿瘤学组的报告
7. Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group [O] . Suman Malempati, Brenda Weigel, Ashish M. Ingle, 2012

机译：Cixutumumab在难治性固体肿瘤的儿科患者中的I / II试验和药代动力学研究和育种肉瘤：儿童肿瘤学群的报告

Phase II Study of Cixutumumab in Combination With Temsirolimus in Pediatric Patients and Young Adults With Recurrent or Refractory Sarcoma: A Report From the Children's Oncology Group

摘要

著录项

相似文献

相关主题

期刊订阅